NVNovavax NVAX · NASDAQ
$11.01 -3.67% (-$0.42)
- Market cap
- $1.78B
- Enterprise value
- $1.89B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 4.3x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -36.5%
- Gross margin
- 77.9%
- Net margin
- -59.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.44
- Free float
- 88.6%
About the company
Novavax (NVAX) is a biotechnology company focused on developing innovative vaccine technologies. Their main goal is to provide effective and safe vaccinations against infectious diseases. Currently, Novavax is dedicated to the development of a vaccine for respiratory viruses, including COVID-19. Novavax stock is suitable for investors who closely follow the biotechnology industry and seek opportunities in the healthcare sector. Add Novavax stock to your watchlist on Bulios and stay informed about the latest developments and news regarding this innovative biotech company.
Sector
Healthcare
Industry
Biotechnology
CEO
John Charles Jacobs
Employees
749
Headquarters
Gaithersburg
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number